ProMIS Neurosciences, Inc.
PMN
ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson's d…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$39M
▼ -1529.3% YoY
Op. Margin
–
ROIC
-83.85%
▼ -253.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$41M
▼ -3.4% YoY
Op. Cash Flow (TTM)
-$41M
▼ -3.4% YoY
Net Debt
-$44M
Net Cash Position
Cash & Equiv.
$44M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PMN
ProMIS Neurosciences (PMN) in two numbers
Questions about ProMIS Neurosciences
Does ProMIS Neurosciences (PMN) pay a dividend?
No. ProMIS Neurosciences (PMN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PMN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PMN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.